Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 2
1976 3
1977 4
1978 11
1979 2
1980 11
1981 8
1982 14
1983 10
1984 10
1985 10
1986 12
1987 8
1988 10
1989 9
1990 5
1991 8
1992 10
1993 4
1994 7
1995 5
1996 4
1997 4
1998 5
1999 4
2000 8
2001 3
2002 2
2003 1
2004 4
2005 2
2006 2
2007 1
2008 1
2009 3
2010 3
2011 1
2012 1
2015 4
2016 4
2017 1
2018 2
2019 2
2020 2
2021 4
2022 4
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, Dekdebrun J, Dilek N, Zizzi C, Johnson N, Puwanant A, Tawil R, Schifitto G, Beck CA, Richeson JF, Zareba W, Thornton C, McDermott MP, Moxley R 3rd. Heatwole C, et al. Neurology. 2021 Jan 12;96(2):e228-e240. doi: 10.1212/WNL.0000000000011002. Epub 2020 Oct 12. Neurology. 2021. PMID: 33046619 Free PMC article. Clinical Trial.
OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients with myotonic dystrophy type 1 (DM1). ...Changes in PR, QRS, and QTc intervals were similar in mexiletine- and placebo-treated partici …
OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients w …
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK, Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF, Tang AS. Sapp JL, et al. N Engl J Med. 2016 Jul 14;375(2):111-21. doi: 10.1056/NEJMoa1513614. Epub 2016 May 5. N Engl J Med. 2016. PMID: 27149033 Free article. Clinical Trial.
The dose of amiodarone was increased if it had been less than 300 mg per day or mexiletine was added if the dose was already at least 300 mg per day. ...
The dose of amiodarone was increased if it had been less than 300 mg per day or mexiletine was added if the dose was already at least …
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
Barohn RJ, Gajewski B, Pasnoor M, Brown A, Herbelin LL, Kimminau KS, Mudaranthakam DP, Jawdat O, Dimachkie MM; Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Study Team; Iyadurai S, Stino A, Kissel J, Pascuzzi R, Brannagan T, Wicklund M, Ahmed A, Walk D, Smith G, Quan D, Heitzman D, Tobon A, Ladha S, Wolfe G, Pulley M, Hayat G, Li Y, Thaisetthawatkul P, Lewis R, Biliciler S, Sharma K, Salajegheh K, Trivedi J, Mallonee W, Burns T, Jacoby M, Bril V, Vu T, Ramchandren S, Bazant M, Austin S, Karam C, Hussain Y, Kutz C, Twydell P, Scelsa S, Kushlaf H, Wymer J, Hehir M, Kolb N, Ralph J, Barboi A, Verma N, Ahmed M, Memon A, Saperstein D, Lou JS, Swenson A, Cash T. Barohn RJ, et al. JAMA Neurol. 2021 Jan 1;78(1):68-76. doi: 10.1001/jamaneurol.2020.2590. JAMA Neurol. 2021. PMID: 32809014 Free PMC article. Clinical Trial.
OBJECTIVE: To determine which medication (pregabalin, duloxetine, nortriptyline, or mexiletine) is most effective for reducing neuropathic pain and best tolerated in patients with CSPN. ...The probability each medication yielded the highest utility was 0.52 for nortriptyli …
OBJECTIVE: To determine which medication (pregabalin, duloxetine, nortriptyline, or mexiletine) is most effective for reducing neurop …
Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.
Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kishimoto Y, Kinoshita F, Hirakawa A, Shimizu S, Nakamura T, Katsuno M. Yamada S, et al. Ann Clin Transl Neurol. 2022 Nov;9(11):1702-1714. doi: 10.1002/acn3.51667. Epub 2022 Oct 8. Ann Clin Transl Neurol. 2022. PMID: 36208052 Free PMC article. Clinical Trial.
There was no difference in distal latencies at room temperature and under cold exposure between mexiletine and placebo groups as the primary endpoint. However, tongue pressure and 10-sec grip and release test under cold exposure were improved in the mexiletine group …
There was no difference in distal latencies at room temperature and under cold exposure between mexiletine and placebo groups as the …
A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Shibuya K, Misawa S, Kimura H, Noto Y, Sato Y, Sekiguchi Y, Iwai Y, Mitsuma S, Beppu M, Watanabe K, Fujimaki Y, Tsuji Y, Shimizu T, Mizuno T, Nakagawa M, Sawaguchi K, Hanaoka H, Kuwabara S. Shibuya K, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):353-8. doi: 10.3109/21678421.2015.1038277. Epub 2015 May 11. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 25960085 Clinical Trial.
This objective of this trial is to study the efficacy and safety of mexiletine, a sodium channel blocker, for ALS. Sixty eligible participants were randomly allocated (1:1) to riluzole 100 mg or riluzole plus mexiletine 300 mg. ...In conclusion, the results suggest …
This objective of this trial is to study the efficacy and safety of mexiletine, a sodium channel blocker, for ALS. Sixty eligible par …
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group. Weiss MD, et al. Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24. Neurology. 2016. PMID: 26911633 Free PMC article. Clinical Trial.
METHODS: Sixty participants with SALS from 10 centers were randomized 1:1:1 to placebo, mexiletine 300 mg/d, or mexiletine 900 mg/d and followed for 12 weeks. ...Mexiletine treatment resulted in large dose-dependent reductions in muscle cramp frequency and se …
METHODS: Sixty participants with SALS from 10 centers were randomized 1:1:1 to placebo, mexiletine 300 mg/d, or mexiletine 900 …
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.
Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG; Consortium for Clinical Investigation of Neurologic Channelopathies. Statland JM, et al. JAMA. 2012 Oct 3;308(13):1357-65. doi: 10.1001/jama.2012.12607. JAMA. 2012. PMID: 23032552 Free PMC article. Clinical Trial.

OBJECTIVE: To determine the effects of mexiletine for symptoms and signs of myotonia in patients with NDMs. ...Mexiletine improved the INQOL-QOL score (mexiletine, 14.0 vs placebo, 16.7; difference, -2.69; 95% CI, -4.07 to -1.30; P < .001) and decreased ha

…
OBJECTIVE: To determine the effects of mexiletine for symptoms and signs of myotonia in patients with NDMs. ...Mexiletine impr …
A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team.
Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, Marra CM, McKendall R, Singer E, Dal Pan GJ, Clifford DB, Tucker T, Cohen B. Kieburtz K, et al. Neurology. 1998 Dec;51(6):1682-8. doi: 10.1212/wnl.51.6.1682. Neurology. 1998. PMID: 9855523 Clinical Trial.
Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. METHOD: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. ...RESUL …
Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. METHOD: A …
Hemodynamic effects of mexiletine.
Shanks RG. Shanks RG. Am Heart J. 1984 May;107(5 Pt 2):1065-71. doi: 10.1016/0002-8703(84)90176-5. Am Heart J. 1984. PMID: 6372422 Review.
A review of studies of mexiletine, a class I antiarrhythmic drug, supports its use in patients with ventricular arrhythmias or in sinus rhythm. ...Some studies are open and others are controlled to compare mexiletine to placebo or to lidocaine. Mexiletine in …
A review of studies of mexiletine, a class I antiarrhythmic drug, supports its use in patients with ventricular arrhythmias or in sin …
Mexiletine or catheter ablation after amiodarone failure in the VANISH trial.
Deyell MW, Steinberg C, Doucette S, Parkash R, Nault I, Gray C, Essebag V, Gardner M, Sterns LD, Healey JS, Hruczkowski T, Rivard L, Leong-Sit P, Nery PB, Sapp JL. Deyell MW, et al. J Cardiovasc Electrophysiol. 2018 Apr;29(4):603-608. doi: 10.1111/jce.13431. Epub 2018 Feb 1. J Cardiovasc Electrophysiol. 2018. PMID: 29356207 Clinical Trial.
We examined the relative efficacy of adjunctive mexiletine and catheter ablation among patients enrolled in the VANISH trial. ...Per protocol, subjects randomized to escalated drug therapy received adjunctive mexiletine. RESULTS: Nineteen of the 259 patients were re …
We examined the relative efficacy of adjunctive mexiletine and catheter ablation among patients enrolled in the VANISH trial. ...Per …
232 results